Target CD47 Differently
ADVANCING A HIGHLY-DIFFERENTIATED ANTI-CD47 ANTIBODY TO TREAT CANCER
At Arch Oncology, we discover and develop new biologic therapeutics to treat patients living with cancer. We are committed to advancing antibodies with best-in-class potential.
Our lead molecule, AO-176, is an IgG2 CD47 targeted antibody, which blocks the “do not eat me” signal enabled by CD47’s interaction with SIRPa and induces phagocytosis.
In addition, AO-176 exhibits:
- Lower binding to normal cells in general and negligible binding to red blood cells
- Enhanced binding to CD47 at acidic pH found in tumor microenvironments
- Programmed and immunogenic cell death
These highly differentiated features of AO-176 offer a potential best-in-class profile
Arch Oncology has two bases. Our headquarters is in Brisbane, CA, a gateway of biotechnology innovation, and our scientific research laboratory is in St. Louis, MO, home of the Gateway Arch.